Context Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Lehr Martin A., was filed 10 Jun 2025.
Who traded when
BuySaleSince the insiders bought
- +129.0%Entry US$0.62 · Close at T+365 US$1.42
- +129.0%Entry US$0.62 · Close at T+365 US$1.42
- +129.0%Entry US$0.62 · Close at T+365 US$1.42
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 100,000 shares@ US$0.700811.6% of flowCommon StockSEC:0001842952-25-000064:0Canonical exit: 7 Sept 2025 (T+90)
- 20,000 shares@ US$0.57636.2% of flowCommon StockSEC:0001842952-25-000062:0Canonical exit: 4 Sept 2025 (T+90)
- 40,010 shares@ US$0.63733.6% of flowCommon StockSEC:0001842952-25-000060:0Canonical exit: 4 Sept 2025 (T+90)
- 5,823 shares@ US$0.84150.9% of flowCommon StockSEC:0001842952-23-000030:0Canonical exit: 22 May 2023 (T+90)
- 5,606 shares@ US$0.87420.9% of flowCommon StockSEC:0001842952-23-000020:0Canonical exit: 14 May 2023 (T+90)
- 5,040 shares@ US$0.97230.9% of flowCommon StockSEC:0001842952-23-000017:0Canonical exit: 7 May 2023 (T+90)
- 7,027 shares@ US$0.69740.9% of flowCommon StockSEC:0001842952-23-000012:0Canonical exit: 30 Apr 2023 (T+90)
- 6,839 shares@ US$0.71660.9% of flowCommon StockSEC:0001842952-23-000008:0Canonical exit: 23 Apr 2023 (T+90)
- 6,783 shares@ US$0.73640.9% of flowCommon StockSEC:0001842952-23-000006:0Canonical exit: 17 Apr 2023 (T+90)
- 20,000 shares@ US$0.73982.6% of flowCommon StockSEC:0001842952-22-000112:0Canonical exit: 16 Mar 2023 (T+90)
- 25,000 shares@ US$0.7426.3% of flowCommon StockSEC:0001842952-22-000114:0Canonical exit: 16 Mar 2023 (T+90)
- 6,000 shares@ US$0.849117.4% of flowCommon StockSEC:0001842952-22-000110:0Canonical exit: 9 Mar 2023 (T+90)
- 13,000 shares@ US$1.85114.5% of flowCommon StockSEC:0001842952-22-000081:0Canonical exit: 17 Nov 2022 (T+90)
- 15,000 shares@ US$1.8040.1% of flowCommon StockSEC:0001842952-22-000079:0Canonical exit: 15 Nov 2022 (T+90)
- 10,000 shares@ US$1.95100.0% of flowCommon StockSEC:0001842952-22-000077:0Canonical exit: 14 Nov 2022 (T+90)
- 13,000 shares@ US$3.21927.0% of flowCommon StockSEC:0001842952-21-000029:0Canonical exit: 16 Mar 2022 (T+90)
- 210,715 sharesCommon StockSEC:0001842952-21-000027:1
- 586,475 sharesCommon StockSEC:0001842952-21-000027:2
- 26,587 sharesCommon StockSEC:0001842952-21-000025:0
- 52,680 shares@ US$7.14Common StockSEC:0001179110-21-009609:1
- 210,722 sharesCommon StockSEC:0001179110-21-009609:2
- 586,476 sharesCommon StockSEC:0001179110-21-009609:3
- 10,000 shares@ US$5.008.1% of flowCommon StockSEC:0001179110-21-009609:0Canonical exit: 20 Jan 2022 (T+90)
- 3,000 shares@ US$5.0046.4% of flowCommon StockSEC:0001179110-21-009610:0Canonical exit: 20 Jan 2022 (T+90)
- 26,587 sharesCommon StockSEC:0001179110-21-009608:0
25 of 25 declarations
About Context Therapeutics Inc.
Martin A. Lehr, chief executive officer of Context Therapeutics Inc., signs 16 of the 25 filings, 11 of them purchases: EUR 61,323 on June 9, 2025, EUR 43,009 and EUR 37,065, the latter on December 16, 2021. From June 6 to June 9, 2025, 3 insiders bought EUR 93,632. In all, 18 purchases come to EUR 319,619, with a median of EUR 13,404, and no sale is recorded.
Alex C. Levit, chief legal officer and corporate secretary, and Jennifer Lynn Minai-Azary, chief financial officer, each made 3 purchases across 3 filings, and Tarek Sahmoud, chief medical officer, one. Evan G. Dick, SVP of R&D, appears twice with no purchase or sale.
Read moreShow less
Five insiders filed 25 times, 10 in 2021 and 6 in each of 2022 and 2023. Filings are published a median of 3 days after the trade. For the 18 purchases with a stored result, the 90-day median is minus 26.2%, with 28% of results positive (recorded past results, not a forecast). The Nasdaq-listed Health Care company has a market capitalisation of USD 22,418,520, and insiders hold 1.6%. There is no filing over the last twelve months.
